Top

Published in:

01-04-2009 | Movement Disorders - Original Article

Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson’s disease patients

Authors: Claudia Funke, Anne S. Soehn, Juergen Tomiuk, Olaf Riess, Daniela Berg

Published in: Journal of Neural Transmission | Issue 4/2009

Abstract

Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons and the presence of intracytoplasmic inclusions (Lewy bodies). Iron, which is elevated in the substantia nigra of PD patients, seems to be of pivotal importance, because of its capacity to enhance the amplification of reactive oxygen species. As iron enters and exits the brain via transport proteins in the blood-brain barrier (BBB), these proteins may represent candidates for a genetic susceptibility to PD. P-glycoprotein (P-gp) is one important efflux pump in the BBB. There is evidence that the function of P-gp is impaired in PD patients. In the current study we examined ten coding single nucleotide polymorphisms in the multidrug resistance gene 1 (MDR1) encoding P-gp to assess whether certain genotypes are associated with PD. However, genotyping of 300 PD patients and 302 healthy controls did not reveal a significant association between coding MDR1 gene polymorphisms and PD.

Bain LJ, LeBlanc GA (1996) Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol Appl Pharmacol 141:288–298PubMed

Bartels AL, van Berckel BN, Lubberink M et al (2008a) Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson’s disease. Parkinsonism Relat Disord 14:505–508PubMedCrossRef

Bartels AL, Willemsen AT, Kortekaas R et al (2008b) Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J Neural Transm 115:1001–1009PubMedCrossRef

Berg D (2006) Transcranial sonography in the early and differential diagnosis of Parkinson’s disease. J Neural Transm Suppl 70:249–254PubMedCrossRef

Berg D, Becker G, Zeiler B et al (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026–1031PubMed

Berg D, Gerlach M, Youdim MB et al (2001a) Brain iron pathways and their relevance to Parkinson’s disease. J Neurochem 79:225–236PubMedCrossRef

Berg D, Jabs B, Merschdorf U et al (2001b) Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 50:463–467PubMedCrossRef

Berg D, Roggendorf W, Schroder U et al (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999–1005PubMedCrossRef

Berg D, Hochstrasser H, Schweitzer KJ et al (2006) Disturbance of iron metabolism in Parkinson’s disease—ultrasonography as a biomarker. Neurotox Res 9:1–13PubMedCrossRef

Borie C, Gasparini F, Verpillat P et al (2002) Association study between iron-related genes polymorphisms and Parkinson’s disease. J Neurol 249:801–804PubMedCrossRef

Drozdzik M, Bialecka M, Mysliwiec K et al (2003) Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics 13:259–263PubMedCrossRef

Excoffier L, Laval G, Schneider S (2005) Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinforma 1:47–50

Furuno T, Landi MT, Ceroni M et al (2002) Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics 12:529–534PubMedCrossRef

Jaccard J, Wan CK (1996) LISREL approaches to interaction effects in multiple regressions. Sage Publications, Thousand Oaks

Kortekaas R, Leenders KL, van Oostrom JC et al (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57:176–179PubMedCrossRef

Kubo S, Hattori N, Mizuno Y (2006) Recessive Parkinson’s disease. Mov Disord 21:885–893PubMedCrossRef

Lee CG, Tang K, Cheung YB et al (2004) MDR1, the blood-brain barrier transporter, is associated with Parkinson’s disease in ethnic Chinese. J Med Genet 41:e60PubMedCrossRef

Litvan I, Halliday G, Hallett M et al (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol 66:251–257PubMedCrossRef

Moos T, Rosengren Nielsen T, Skjorringe T et al (2007) Iron trafficking inside the brain. J Neurochem 103:1730–1740PubMedCrossRef

Ohtsuki S, Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24:1745–1758PubMedCrossRef

Raymond M, Rousset F (1995) GENEPOP (Version 1.2): population genetics software for exact tests and ecumenicism. J Hered 86:248–249

Rouault TA, Cooperman S (2006) Brain iron metabolism. Semin Pediatr Neurol 13:142–148PubMedCrossRef

Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics methods and protocols: methods in molecular biology. Humana Press, Totowa

Tan EK, Skipper LM (2007) Pathogenic mutations in Parkinson disease. Hum Mutat 28:641–653PubMedCrossRef

Tan EK, Chan DK, Ng PW et al (2005) Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol 62:460–464PubMedCrossRef

Title: Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson’s disease patients
Authors: Claudia Funke
Anne S. Soehn
Juergen Tomiuk
Olaf Riess
Daniela Berg
Publication date: 01-04-2009
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 4/2009
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-009-0196-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson’s disease patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Roles of GABAB receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release

Na+,K+-ATPase activity in an animal model of mania

Globus pallidus internus firing rate modification after motor-imagination in three Parkinson’s disease patients

Lipopolysaccharide mitagates methamphetamine-induced striatal dopamine depletion via modulating local TNF-α and dopamine transporter expression

Neuregulin 1 and age of onset in the major psychoses

Expression of four housekeeping proteins in elderly patients with schizophrenia